Доступ предоставлен для: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems
Главный редактор: Mandip Sachdeva Singh (open in a new tab)

Выходит 6 номеров в год

ISSN Печать: 0743-4863

ISSN Онлайн: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Gene Modulation for Treating Liver Fibrosis

Том 24, Выпуск 2, 2007, pp. 93-146
DOI: 10.1615/CritRevTherDrugCarrierSyst.v24.i2.10
Get accessGet access

Краткое описание

Despite tremendous progress in our understanding of fibrogenesis, injury stimuli process, inflammation, and hepatic stellate cell (HSC) activation, there is still no standard treatment for liver fibrosis. Delivery of small molecular weight drugs, proteins, and nucleic acids to specific liver cell types remains a challenge due to the overexpression of extracellular matrix (ECM) and consequent closure of sinusoidal gaps. In addition, activation of HSCs and subsequent release of inflammatory cytokines and infiltration of immune cells are other major obstacles to the treatment of liver fibrosis. To overcome these barriers, different therapeutic approaches are being investigated. Among them, the modulation of certain aberrant protein production is quite promising for treating liver fibrosis. In this review, we describe the mechanism of antisense, antigene, and RNA interference (RNAi) therapies and discuss how the backbone modification of oligonucleotides affects their in vivo stability, biodistribution, and bioactivity. Strategies for delivering these nucleic acids to specific cell types are discussed. This review critically addresses various insights developed with each individual strategy and for multipronged approaches, which will be helpful in achieving more effective outcomes.

ЦИТИРОВАНО В
  1. Shaker Olfat Gamil, Sadik Nermin A.H., El-Dessouki Abeer, Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide −443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C, Human Immunology, 73, 10, 2012. Crossref

  2. Staten Nicholas R, Welsh Eric A, Sidik Kurex, McDonald Sandra A, Dufield Dawn R, Maqsodi Botoul, Ma Yunqing, McMaster Gary K, Mathews Rodney W, Arch Robert H, Masferrer Jaime L, Souberbielle Bernard E, Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis, Fibrogenesis & Tissue Repair, 5, 1, 2012. Crossref

  3. Shaker Olfat, El-Shehaby Amal, Fayez Salwa, Zahra Amr, Marzouk Samar, Raziky Maissa El, Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4, Cell Biochemistry and Function, 2013. Crossref

  4. Ghazwani Mohammed, Zhang Yifei, Gao Xiang, Fan Jie, Li Jiang, Li Song, Anti-fibrotic effect of thymoquinone on hepatic stellate cells, Phytomedicine, 21, 3, 2014. Crossref

  5. Wu Yuan-Yuan, Chen Li, Wang Gui-Lan, Zhang Yi-Xin, Zhou Jia-Ming, He Song, Qin Jing, Zhu Yuan-Yuan, Inhibition of hepatocellular carcinoma growth and angiogenesis by dual silencing of NET-1 and VEGF, Journal of Molecular Histology, 44, 4, 2013. Crossref

  6. Imran Muhammad, Manzoor Sobia, Parvaiz Fahed, Predictive Potential of IL-18 −607 and Osteopontin −442 Polymorphism in Interferon-Based Therapy of HCV Infection in the Pakistani Population, Viral Immunology, 27, 8, 2014. Crossref

  7. Bittnerová Lenka, Jiroutová Alena, Rudolf Emil, Řezáčová Martina, Kanta Jiří, EFFECT OF COLLAGEN I GEL ON APOPTOSIS OF RAT HEPATIC STELLATE CELLS, Acta Medica (Hradec Kralove, Czech Republic), 56, 2, 2013. Crossref

  8. Nie Qing-He, Zhu Chuan-Long, Zhang Ya-Fei, Yang Jie, Zhang Jiu-Cong, Gao Ren-Tao, Inhibitory Effect of Antisense Oligonucleotide Targeting TIMP-2 on Immune-Induced Liver Fibrosis, Digestive Diseases and Sciences, 55, 5, 2010. Crossref

  9. Kumar Virender, Mahato Ram I., Delivery and Targeting of miRNAs for Treating Liver Fibrosis, Pharmaceutical Research, 32, 2, 2015. Crossref

  10. Truong Hai Nhung, Nguyen Hai Nam, Nguyen Thi Kim Nguyen, Le Minh Huy, Tran Huong Giang, Huynh Nghia, Van Nguyen Thanh, Establishment of a standardized mouse model of hepatic fibrosis for biomedical research, Biomedical Research and Therapy, 1, 2, 2014. Crossref

  11. Yang Ningning, Singh Saurabh, Mahato Ram I., Targeted TFO delivery to hepatic stellate cells, Journal of Controlled Release, 155, 2, 2011. Crossref

  12. Huang Wenbao, Zhu Guoxian, Huang Meixian, Lou Guoqiang, Liu Yi, Wang Shuying, Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects, Clinica Chimica Acta, 411, 9-10, 2010. Crossref

  13. Shukla Ravi S., Qin Bin, Wan Yu-Jui Yvonne, Cheng Kun, PCBP2 siRNA Reverses the Alcohol-induced Pro-fibrogenic Effects in Hepatic Stellate Cells, Pharmaceutical Research, 28, 12, 2011. Crossref

  14. Mahato Rubi, Qin Bin, Cheng Kun, Blocking IKKα Expression Inhibits Prostate Cancer Invasiveness, Pharmaceutical Research, 28, 6, 2011. Crossref

  15. Panakanti Ravikiran, Pratap Akshay, Yang Ningning, Jackson John S., Mahato Ram I., Triplex forming oligonucleotides against type α1(I) collagen attenuates liver fibrosis induced by bile duct ligation, Biochemical Pharmacology, 80, 11, 2010. Crossref

  16. JI ZHOU-JING, WANG JIAN-LI, CHEN LI, Inhibition of skin squamous cell carcinoma proliferation and promote apoptosis by dual silencing of NET-1 and survivin, Oncology Reports, 34, 2, 2015. Crossref

  17. Wang Ning, Xu Qihe, Tan Hor Yue, Hong Ming, Li Sha, Yuen Man-Fung, Feng Yibin, Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells, Evidence-Based Complementary and Alternative Medicine, 2016, 2016. Crossref

  18. Liu Hao, Chen Zhijin, Jin Wei, Barve Ashutosh, Wan Yu-Jui Yvonne, Cheng Kun, Silencing of α-complex protein-2 reverses alcohol- and cytokine-induced fibrogenesis in hepatic stellate cells, Liver Research, 1, 1, 2017. Crossref

  19. Zhao Zhen, Li Yuanke, Jain Akshay, Chen Zhijin, Liu Hao, Jin Wei, Cheng Kun, Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells, Nanomedicine: Nanotechnology, Biology and Medicine, 14, 1, 2018. Crossref

  20. Dong Miao-Xian, Jia Yan, Zhang Ying-Bo, Li Cheng-Chong, Geng Yu-Tao, Zhou Li, Li Xue-Yan, Liu Ji-Cheng, Niu Ying-Cai, Emodin protects rat liver from CCl4-induced fibrogenesis via inhibition of hepatic stellate cells activation, World Journal of Gastroenterology, 15, 38, 2009. Crossref

  21. Jain Akshay, Barve Ashutosh, Zhao Zhen, Fetse John Peter, Liu Hao, Li Yuanke, Cheng Kun, Targeted Delivery of an siRNA/PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride‐Induced Liver Fibrosis, Advanced Therapeutics, 2, 8, 2019. Crossref

  22. Steer Clifford J., Kren Betsy T., Reversing Age-Related DNA Damage Through Engineered DNA Repair, in The Future of Aging, 2010. Crossref

  23. Zhao Zhen, Lin Chien-Yu, Cheng Kun, siRNA- and miRNA-based therapeutics for liver fibrosis, Translational Research, 214, 2019. Crossref

  24. Cheng Kun, Qin Bin, RNA Interference for Cancer Therapy, in Pharmaceutical Perspectives of Cancer Therapeutics, 2009. Crossref

  25. Bae Junghan, Jang Eungyeong, Lee Jang-Hoon, Kyungheechunggan-tang suppresses inflammatory cytokines and fibrotic genes in LPS-induced RAW 264.7 cells and LX-2 cells, Journal of Korean Medicine, 39, 4, 2018. Crossref

  26. Flood Hannah M., Bolte Craig, Dasgupta Nupur, Sharma Akanksha, Zhang Yufang, Gandhi Chandrashekhar R., Kalin Tanya V., Kalinichenko Vladimir V., The forkhead box F1 transcription factor inhibits collagen deposition and accumulation of myofibroblasts during liver fibrosis, Biology Open, 2019. Crossref

  27. Tai Wanyi, Qin Bin, Cheng Kun, Inhibition of Breast Cancer Cell Growth and Invasiveness by Dual Silencing of HER-2 and VEGF, Molecular Pharmaceutics, 7, 2, 2010. Crossref

  28. Yang Ningning, Ye Zhaoyang, Li Feng, Mahato Ram I., HPMA Polymer-Based Site-Specific Delivery of Oligonucleotides to Hepatic Stellate Cells, Bioconjugate Chemistry, 20, 2, 2009. Crossref

  29. Yasmin Alvi, Regan Daniel P., Schook Lawrence B., Gaba Ron C., Schachtschneider Kyle M., Transcriptional regulation of alcohol induced liver fibrosis in a translational porcine hepatocellular carcinoma model, Biochimie, 182, 2021. Crossref

  30. Shukla Ravi S., Tai Wanyi, Mahato Rubi, Jin Wei, Cheng Kun, Development of Streptavidin-Based Nanocomplex for siRNA Delivery, Molecular Pharmaceutics, 10, 12, 2013. Crossref

  31. Chen Zhijin, Jin Wei, Liu Hao, Zhao Zhen, Cheng Kun, Discovery of Peptide Ligands for Hepatic Stellate Cells Using Phage Display, Molecular Pharmaceutics, 12, 6, 2015. Crossref

  32. Wu Pengkai, Luo Xinping, Wu Hui, Zhang Qingyan, Dai Yuanxin, Sun Minjie, Efficient and targeted chemo-gene delivery with self-assembled fluoro-nanoparticles for liver fibrosis therapy and recurrence, Biomaterials, 261, 2020. Crossref

  33. Wu Pengkai, Luo Xinping, Sun Meiling, Sun Beicheng, Sun Minjie, Synergetic regulation of kupffer cells, extracellular matrix and hepatic stellate cells with versatile CXCR4-inhibiting nanocomplex for magnified therapy in liver fibrosis, Biomaterials, 284, 2022. Crossref

  34. Li Chunxue, Zhan Yating, Zhang Rongrong, Tao Qiqi, Lang Zhichao, Zheng Jianjian, 20(S)- Protopanaxadiol suppresses hepatic stellate cell activation via WIF1 demethylation-mediated inactivation of the Wnt/β-catenin pathway, Journal of Ginseng Research, 2022. Crossref

Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции Цены и условия подписки Begell House Контакты Language English 中文 Русский Português German French Spain